Vascular BioSciences

Vascular BioSciences (VBS) is a biopharmaceutical and medical device company focused on developing targeted solutions for difficult-to-treat cardiovascular and inflammatory diseases. The company’s core technology is the CAR peptide (CARSKNKDC), a 9-amino-acid cyclic peptide that selectively targets and penetrates diseased tissues by binding to heparan sulfate moieties. VBS operates through three main divisions: VBS Pharmaceuticals, which develops targeted therapies like CAR-modified liposomes for pulmonary hypertension and sepsis; VBS Interventional, which created the world’s first endoarterial biopsy catheter; and VBS Molecular Diagnostics, which provides transcriptional profiling of vascular tissue. The company is currently advancing its lead programs toward clinical trials, with a particular focus on pulmonary arterial hypertension and acute respiratory conditions.